Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT + Pembrolizumab + Chemotherapy in High-Risk, Early-Stage TNBC or HR-low+/HER2- Breast Cancer
NCT06966700Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Primary completion
- Mar 2033
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 41
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in breast cancer (2 arms), sponsored by Merck & Co. Primary endpoints: Pathological Complete Response at 30 weeks and Event-Free Survival at 92 months. Started Jun 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06966700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966700.